Date:1/21/2011

existing trends and information. Watson disclaims any intent or obligation to update these forward-looking statements. Any statements in this press release that refer to Watson's financial results for 2010 are preliminary and reflect our expected financial results as of the date of this presentation, and are subject to change.  Watson disclaims any intent or obligation to update these statements.  Actual results may differ materially from current expectations depending upon a number of factors affecting Watson's business or estimates. These factors include, among others,  the inherent uncertainty associated with financial estimates; the possibility that the financial estimates will change after further review by Watson's management or outside independent accountants or due to the discovery of additional or revised information or subsequent events; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; market acceptance of and continued demand for Watson's products; the impact of competitive products and pricing; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful implementation of strategic initiatives; fluctuations in foreign currency exchange rates; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations; uncertainties related to the timing and outcome of litigation; changes in laws and regulations, including Medicare and Medicaid and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical
'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
2. Watson Announces Preliminary Financial Performance for FY 2010
3. Watson to Host Investor Day on January 21 in New York City
4. Watsons Generic Fentora® Receives FDA Approval
5. Watson to Present at the 29th Annual JP Morgan Healthcare Conference
6. Watson Announces Novel Oral Contraceptive Approval
7. Watson and Richter Announce Exclusive License Agreement for Esmya™
8. Watson Confirms Exalgo™ Patent Challenge
9. Watson Announces Pricing of Secondary Offering By Selling Stockholder
10. Watson Announces Commencement of Secondary Offering by Selling Stockholder
11. Watson To Present At The 2010 Credit Suisse Healthcare Conference